Lack of pharmacokinetic interaction between tesaglitazar and metformin in healthy male subjects

被引：0
|
作者：
Ågren, AC
Ericsson, H
Halldórsdóttir, S
Johnsson, K
Tellow, K
Öhman, P
机构：
来源：
DIABETES | 2005年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A517 / A517
页数：1
相关论文
共 50 条
  • [21] Lack of a Pharmacokinetic Interaction Between Saxagliptin and Dapagliflozin in Healthy Subjects: A Randomized Crossover Study
    Vakkalagadda, Blisse
    Lubin, Susan
    Reynolds, Laurie
    Liang, Dan
    Marion, Alan S.
    LaCreta, Frank
    Boulton, David W.
    CLINICAL THERAPEUTICS, 2016, 38 (08) : 1890 - 1899
  • [22] Lack of pharmacokinctic interaction between alogliptin benzoate (SYR-322) and metformin in healthy subjects
    Covington, Paul
    Christopher, Ronald
    Davenport, Michael
    Fleck, Penny
    Mekki, Qais
    Wann, Elisabeth
    Karim, Aziz
    DIABETES, 2007, 56 : A541 - A542
  • [23] LACK OF PHARMACOKINETIC INTERACTION BETWEEN DAPAGLIFLOZIN AND PIOGLITAZONE IN HEALTHY
    Li, T.
    Roche, J.
    Zhang, W.
    Pfister, M.
    Liu, X.
    Usansky, H.
    Maurer, C.
    Shyu, W.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09): : 1093 - 1093
  • [24] LACK OF A CLINICALLY MEANINGFUL PHARMACOKINETIC INTERACTION BETWEEN ERTUGLIFLOZIN AND GLIMEPIRIDE OR SIMVASTATIN IN HEALTHY SUBJECTS.
    Sahasrabudhe, V.
    Kumar, V.
    Matschke, K.
    Shi, H.
    Alvey, C.
    Liang, Y.
    Fountaine, R. J.
    Hickman, A.
    Saur, D.
    Terra, S. G.
    Zhou, S.
    Cutler, D. L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S46 - S47
  • [25] Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects
    Kasichayanula, S.
    Liu, X.
    Shyu, W. C.
    Zhang, W.
    Pfister, M.
    Griffen, S. C.
    Li, T.
    LaCreta, F. P.
    Boulton, D. W.
    DIABETES OBESITY & METABOLISM, 2011, 13 (01): : 47 - 54
  • [26] Lack of pharmacokinetic interaction between retigabine and phenobarbital at steady-state in healthy subjects.
    Ferron, GM
    Patat, A
    Parks, V
    Rolan, P
    Troy, S
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P48 - P48
  • [27] Lack of pharmacokinetic interaction between grapefruit juice and phenytoin in healthy male volunteers and epileptic patients
    Kumar, N
    Garg, SK
    Prabhakar, S
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 1999, 21 (09): : 629 - 632
  • [28] Safety and pharmacokinetic interaction between fotagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin in healthy subjects
    Ding, Yanhua
    Zhang, Hong
    Li, Cuiyun
    Zheng, WenBo
    Wang, Meng
    Li, Ying
    Sun, HaiGang
    Wu, Min
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2021, 17 (06) : 725 - 731
  • [29] Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects
    Kim, Heeyoung
    Kim, Choon Ok
    Park, Hyeonsoo
    Park, Min Soo
    Kim, Dasohm
    Hong, Taegon
    Shin, Yesong
    Jin, Byung Hak
    TRANSLATIONAL AND CLINICAL PHARMACOLOGY, 2023, 31 (01) : 59 - 68
  • [30] Pharmacokinetic interaction between verapamil and everolimus in healthy subjects
    Kovarik, JM
    Beyer, D
    Bizot, MN
    Jiang, Q
    Allison, MJ
    Schmouder, RL
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (04) : 434 - 437
12345